Product Description
(Sourced from: https://ankyratx.com/our-pipeline/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Ankyra Therapeutics
Company Location: Eastern America
Company Founding Year: 2020
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/04/2025 |
News Article |
Ankyra Announces Publication of Phase 1 Clinical Data, and Will Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting |